Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442–459. doi:10.1002/ajh.25011
   PubMed Web of Science ®Google Scholar
• Laurent E, Talpaz M, Kantarjian H, et al. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61:2343–2355.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691–709. doi:10.1002/ajh.25792
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe against cancer program. Leukemia. 2003;17:2318–2357. doi:10.1038/sj.leu.2403135
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820. doi:10.1182/blood-2006-02-005686
   PubMed Web of Science ®Google Scholar
• White HE, Salmon M, Albano F, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022;36:1834–1842. doi:10.1038/s41375-022-01607-z
   PubMed Web of Science ®Google Scholar
• Cross NCP, Hochhaus A, Müller MC. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol. 2015;94(Suppl 2):S219–S225. doi:10.1007/s00277-015-2315-1
   PubMedGoogle Scholar
• White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first world health organization international genetic reference panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:e111–e117. doi:10.1182/blood-2010-06-291641
   PubMed Web of Science ®Google Scholar
• Cross NCP, White HE, Ernst T, et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale. Leukemia. 2016;30:1844–1852. doi:10.1038/leu.2016.90
   PubMed Web of Science ®Google Scholar
• Alikian M, Whale AS, Akiki S, et al. RT-qPCR and RT-digital PCR: A comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem. 2017;63(2):525–531. doi:10.1373/clinchem.2016.262824
   PubMed Web of Science ®Google Scholar
• Maier J, Lange T, Cross M, et al. Optimized digital droplet PCR for BCR-ABL. J Mol Diagn. 2019;21:27–37. doi:10.1016/j.jmoldx.2018.08.012
   PubMed Web of Science ®Google Scholar
• Jennings LJ, George D, Czech J, et al. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn. 2014;16:174–179. doi:10.1016/j.jmoldx.2013.10.007
   PubMed Web of Science ®Google Scholar
• Spiess B, Rinaldetti S, Naumann N, et al. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS One. 2019;14(3):e0214305. doi:10.1371/journal.pone.0214305
   PubMed Web of Science ®Google Scholar
• Zanaglio C, Bernardi S, Gandolfi L, et al. RT-qPCR versus digital PCR: how do they impact differently on clinical management of chronic myeloid leukemia patients? Case Rep Oncol. 2020;13(3):1263–1269. doi:10.1159/000510440
   PubMed Web of Science ®Google Scholar
• Radich J, Yeung C, Wu D. New approaches to molecular monitoring in CML (and other diseases). Blood. 2019;134:1578–1584. doi:10.1182/blood.2019000838
   PubMed Web of Science ®Google Scholar
• Shelton DN, Bhagavatula P, Sepulveda N, et al. Performance characteristics of the first food and drug administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia. PLoS One. 2022;17(3):e0265278. doi:10.1371/journal.pone.0265278
   PubMed Web of Science ®Google Scholar
• Franke GN, Maier J, Wildenberger K, et al. Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia. J Mol Diagn. 2020;22:81–89. doi:10.1016/j.jmoldx.2019.08.007
   PubMed Web of Science ®Google Scholar
• Petiti J, Lo Iacono M, Dragani M, et al. Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts. J Clin Med. 2020;9:1457. doi:10.3390/jcm9051457
   PubMed Web of Science ®Google Scholar
• Kockerols CCB, Valk PJM, Levin MD, et al. Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice. Hemasphere. 2020;4(6):e496. doi:10.1097/HS9.0000000000000496
   PubMed Web of Science ®Google Scholar
• Soverini S, Bernardi S, Galimberti S. Molecular testing in CML between Old and New methods: Are We at a turning point? J Clin Med. 2020;9(12):3865. doi:10.3390/jcm9123865
   PubMed Web of Science ®Google Scholar
• Bochicchio MT, Petiti J, Berchialla P, et al. Droplet digital PCR for BCR–ABL1 monitoring in diagnostic routine: ready to start? Cancers (Basel). 2021;13(21):5470. doi:10.3390/cancers13215470
   PubMed Web of Science ®Google Scholar
• dMIQE Group, Huggett JF. The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020. Clin Chem. 2020;66(8):1012–1029. doi:10.1093/clinchem/hvaa125
   PubMed Web of Science ®Google Scholar
• Kjaer L, Skov V, Andersen MT, et al. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay. Eur J Haematol. 2019;103(1):26–34. doi:10.1111/ejh.13238
   PubMed Web of Science ®Google Scholar
• Bernardi S, Bonifacio M, Iurlo A, et al. “Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay.” Is dPCR the key? Eur J Haematol. 2019;103(3):272–273. doi:10.1111/ejh.13282
   PubMed Web of Science ®Google Scholar